Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.
Checked against the public recordLast updated Jun 14, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Augusta University
- Interventions being studied
- Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]; Drug: Irinotecan Injection [Camptosar]
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Confirmed SCLC with known UGT1A genotype. * Patients who have received at least 1 prior platinum-based chemotherapy. * Life expectancy of 3 months or more. * Measurable disease. Exclusion Criteria: * Patients with UGT1A polymorphism. * Currently receiving chemotherapy. * Pregnant and nursing women.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Georgia Cancer Center at AU Medical CenterAugusta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 14, 2022. Always confirm current availability with the study team.